Burning Rock Biotech Ltd. engages in the investment of medical fields. It specializes in next-generation sequencing diagnostics solutions for precision medicine in oncology. The firm operates through the following segments: Central Laboratory Business, In-Hospital Business and Pharma Research and Development Services. Its products and clinical applications include companion diagnostics for targeted therapy and immunotherapy, benign, malignant tumor diagnosis, minimal residual disease monitoring, tumor recurrence and progression prediction and tumor susceptibility tests. The company was founded by Yu Sheng Han in January 2014 and is headquartered in Guangzhou, China.
Mit Spannung erwarten die Markteilnehmer den Jahresauftakt im IPO-Markt. Immerhin war das Jahr 2020 das Erfolgreichste seit 1999. Mit 447 IPOs und einem Emissionsvolumen von 165 Mrd. USD verpasste man nur knapp die Bestmarke von damals, als 547 IPOs 167 Mrd. USD an neuem Kapital einsammeln konnten.
